Oxaliplatin-based chemotherapy in the management of colorectal cancer

References

• Colorectal Cancer Collaborative G. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ321(7260), 531–535 (2000).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.343(13), 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.18(16), 2938–2947 (2000).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol.26(12), 2013–2019 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature26(222), 385–386 (1969).
   Google Scholar
• Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol.25(Suppl. 5), 4–12 (1998).
   PubMed Web of Science ®Google Scholar
• Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel. Biochem. Pharmacol.24(12), 1855–1865 (1996).
   Google Scholar
• Woynarowski JM, Chapman WG, Napier C, Herzig MCS, Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol.54(5), 770–777 (1998).
   PubMed Web of Science ®Google Scholar
• Boyer J, McLean EG, Aroori S et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin. Cancer Res.10(6), 2158–2167 (2004).
   PubMed Web of Science ®Google Scholar
• Synold TW, Takimoto CH, Doroshow JH et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute organ dysfunction working group study. Clin. Cancer Res.13(12), 3660–3666 (2007).
   PubMedGoogle Scholar
• Raymond E, Buquet-Fagot C, Djelloul S et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs8(9), 876–885 (1997).
   PubMed Web of Science ®Google Scholar
• Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin. Cancer Res.5(5), 1189–1196 (1999).
   PubMed Web of Science ®Google Scholar
• Mathé G, Kidani Y, Triana K et al. A Phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed. Pharmacother.40(10), 372–376 (1986).
   PubMed Web of Science ®Google Scholar
• Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol.25(4), 299–303 (1990).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Proc. Am. Soc. Clin. Oncol.25(18S), (2007) (Abstract 4007).
   Google Scholar
• Eloxatin®, product characteristics. Sanofi, Gentilly Cedex, France.
   Google Scholar
• Machover D, Diaz-Rubio E, de Gramont A et al. Two consecutive Phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol.7(1), 95–98 (1996).
   PubMed Web of Science ®Google Scholar
• Levi F, Perpoint B, Garufi C et al. Oxaliplatin activity against metastatic colorectal cancer. A Phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer29(9), 1280–1284 (1993).
   Web of Science ®Google Scholar
• Diaz-Rubio E, Sastre J, Zaniboni A et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a Phase II multicentric study. Ann. Oncol.9(1), 105–108 (1998).
   PubMed Web of Science ®Google Scholar
• Becouarn Y, Ychou M, Ducreux M et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J. Clin. Oncol.16(8), 2739–2744 (1998).
   PubMed Web of Science ®Google Scholar
• De Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer33(2), 214–219 (1997).
   PubMed Web of Science ®Google Scholar
• Andre T, Louvet C, Raymond E, Tournigand C, de Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol.9(11), 1251–1253 (1998).
   PubMed Web of Science ®Google Scholar
• Levi FA, Zidani R, Vannetzel J-M et al. Chronomodulated versus fixed-infusion – rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl Cancer Inst.86(21), 1608–1617 (1994).
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil–leucovorin: interim results of a Phase III Trial. J. Clin. Oncol.21(11), 2059–2069 (2003).
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.22(1), 23–30 (2004).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E et al. FOLFIRI Followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22(2), 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Grothey A, Jordan K, Kellner O et al. Randomized Phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc. Am. Soc. Clin. Oncol.22 (2003) (Abstract 1022).
   Google Scholar
• Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol.22(11), 2084–2091 (2004).
   PubMed Web of Science ®Google Scholar
• Porschen R, Arkenau H-T, Kubicka S et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J. Clin. Oncol.25(27), 4217–4223 (2007).
   PubMed Web of Science ®Google Scholar
• Diaz-Rubio E, Tabernero J, Gomez-Espana A et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the treatment of digestive tumors trial. J. Clin. Oncol.25(27), 4224–4230 (2007).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol.26(12), 2006–2012 (2008).
   PubMed Web of Science ®Google Scholar
• Rothenberg M, Navarro M, Butts CA et al. Capecitabine + oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase II trial results. Eur. J. Cancer5(4) (2007) (Abstract A3012).
   Google Scholar
• Arkenau HT, Graeven U, Kubicka S et al. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin. Colorectal Cancer7(1), 60–64 (2008).
   PubMed Web of Science ®Google Scholar
• Figer A, Perez-Staub N, Carola E et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer110(12), 2666–2671 (2007).
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J. Clin. Oncol.24(25), 4085–4091 (2006).
   PubMed Web of Science ®Google Scholar
• Feliu J, Salud A, Escudero P et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br. J. Cancer94(7), 969–975 (2006).
   PubMed Web of Science ®Google Scholar
• Comella P, Natale D, Farris A et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer104(2), 282–289 (2005).
   PubMed Web of Science ®Google Scholar
• Twelves CJ, Butts CA, Cassidy J et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large Phase II study. Clin. Colorectal Cancer5(2), 101–107 (2005).
   PubMedGoogle Scholar
• Abad A, Massutí B, Antón A et al. Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a Phase II study. Acta Oncol.22, 1–7 (2007).
   Google Scholar
• Masi G, Allegrini G, Cupini S et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a Phase II study with a simplified biweekly schedule. Ann. Oncol.15(12), 1766–1772 (2004).
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol.25(13), 1670–1676 (2007).
   PubMed Web of Science ®Google Scholar
• Souglakos J, Androulakis N, Syrigos K et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised Phase III trial from the Hellenic Oncology Research Group (HORG). Br. J. Cancer94(6), 798–805 (2006).
   PubMed Web of Science ®Google Scholar
• Tabernero J, Van Cutsem E, Diaz-Rubio E et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol.25(33), 5225–5232 (2007).
   PubMed Web of Science ®Google Scholar
• Borner M, Koeberle D, Von Moos R et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized Phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann. Oncol.19(7), 1288–1292 (2008).
   PubMed Web of Science ®Google Scholar
• Venook A, Niedzwiecki D, Hollis D et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc. Am. Soc. Clin. Oncol.24(18S), 3509 (2006).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized Phase II study. Proc. Am. Soc. Clin. Oncol.25(18S), 4035 (2007).
   Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol.25(12), 1539–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Hochster HS, Welles L, Hart L et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. Proc. Am. Soc. Clin. Oncol.23(16S), 3515 (2005).
   Google Scholar
• Hochster HS, Hart L, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J. Clin. Oncol.24(18S), 3510 (2006).
   Web of Science ®Google Scholar
• Bismuth H, Adam R, Lévi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg.224(4), 509–520 (1996).
   PubMed Web of Science ®Google Scholar
• Alberts SR, Donohue JH, Mahoney MR et al. Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: a North Central Cancer Treatment Group (NCCTG) Phase II study. Proc. Am. Soc. Clin. Oncol.22 (2003) (Abstract 1053).
   Google Scholar
• Julie C, Lutz MP, Aust D et al. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup Phase III study 40983. Presented at:2007 Gastrointestinal Cancers Symposium. FL, USA, 19–21 January (2007) (Abstratct 241).
   Google Scholar
• Nordlinger B, Sorbye H, Collette L et al. Final results of the EORTC Intergroup randomized Phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. Proc. Am. Soc. Clin. Oncol.25(18S), (2007) (Abstract LBA5).
   Google Scholar
• Gruenberger B, Scheithauer W, Tamandl D et al. Neoadjuvant chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.24(18S), (2006) (Abstract 3546).
   Google Scholar
• Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol.23(34), 8664–8670 (2005).
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med.350(23), 2343–2351 (2004).
   PubMed Web of Science ®Google Scholar
• Kuebler JP, Wieand HS, O’Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol.25(16), 2198–2204 (2007).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wieand S, Kuebler PJ, Colangelo L, O’Connell MJ, Yothers G. A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: survival results of NSABP protocol C-07. Proc. Am. Soc. Clin. Oncol. (2008) (Abstract LBA4005).
   Google Scholar
• Schmoll H-J, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J. Clin. Oncol.25(1), 102–109 (2007).
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Wolmark N. Initial safety report of NSABP C-08, a randomized Phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. Proc. Am. Soc. Clin. Oncol.26(Suppl. 15), (2008) (Abstract 4006).
   Google Scholar
• Cividalli A, Ceciarelli F, Livdi E et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int. J. Radiat. Oncol. Biol. Phys.52(4), 1092–1098 (2002).
   PubMedGoogle Scholar
• Freyer G, Bossard N, Romestaing P et al. Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 Phase I trial. J. Clin. Oncol.19(9), 2433–2438 (2001).
   PubMed Web of Science ®Google Scholar
• Gerard J-P, Chapet O, Nemoz C et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 Phase II trial. J. Clin. Oncol.21(6), 1119–1124 (2003).
   PubMed Web of Science ®Google Scholar
• Gambacorta MA, Valentini V, Coco C et al. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II–III resectable rectal cancer: Phase I and II studies. Int. J. Radiat. Oncol. Biol. Phys.60(1), 139–148 (2004).
   PubMed Web of Science ®Google Scholar
• Eloxatin®, package insert. Sanofi-Synthelabo, Inc., NY, USA.
   Google Scholar
• Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J. Clin. Oncol.20(7), 1767–1774 (2002).
   PubMed Web of Science ®Google Scholar
• Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol.85(5), 2293–2297 (2001).
   PubMed Web of Science ®Google Scholar
• Luo FR, Wyrick SD, Chaney SG. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother. Pharmacol.44(1), 29–38 (1999).
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F, Tournigand C, Andre T et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann. Oncol.15(8), 1210–1214 (2004).
   PubMedGoogle Scholar
• Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J. Clin. Oncol.24(3), 394–400 (2006).
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F, Lledo G, Chibaudel B et al. OPTIMOX2, a large randomized Phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. Proc. Am. Soc. Clin. Oncol.25(18S) (2007) (Abstract 4013).
   Google Scholar
• Cascinu S, Catalano V, Cordella L et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol.20(16), 3478–3483 (2002).
   PubMed Web of Science ®Google Scholar
• Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol.25(2), 228–234 (1984).
   PubMed Web of Science ®Google Scholar
• Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C. Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study. Dtsch. Med. Wochenschr.127(3), 78–82 (2002).
   PubMed Web of Science ®Google Scholar
• Von Delius S, Eckel F, Wagenpfeil S et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter Phase II study. Invest. New Drugs25(2), 173–180 (2007).
   PubMed Web of Science ®Google Scholar
• Mitchell PL, Goldstein D, Michael M et al. Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin. Colorectal Cancer6(2), 146–151 (2006).
   Google Scholar
• Gamelin L, Boisdron-Celle M, Delva R et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res.10(12), 4055–4061 (2004).
   PubMed Web of Science ®Google Scholar
• Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J. Clin. Oncol.25(25), (2007) (Abstract 4028).
   Google Scholar
• Hochster HS, Grothey A, Shpilsky A, Childs BH. Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial. Presented at: 2008 Gastrointestinal Cancers Symposium. FL, USA, 25–27 January, 2008.
   Google Scholar
• Grothey A, Hart L, Rowland KM et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the Phase III CONcePT trial. Proc. Am. Soc. Clin. Oncol. (2008) (Abstract 4010).
   Google Scholar
• Nikcevich DA, Grothey A, Sloan JA et al. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: results of the Phase III placebo-controlled, double-blind NCCTG trial N04C7. Proc. Am. Soc. Clin. Oncol. (2008) (Abstract 4009).
   Google Scholar
• Gamelin L, Boisdron-Celle M, Morel A et al. Oxaliplatin-related neurotoxicity: interest of calcium–magnesium infusion and no impact on its efficacy. J. Clin. Oncol.26(7), 1188–1189 (2008).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Bjarnason GA, Hickish T et al. Randomized double blind (DB) placebo (Plcb) controlled Phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol.24(18S), (2006) (Abstract 3507).
   Google Scholar
• Agafitei RD, Schneider S, Iqbal S, Yang D, Groshen S, Lenz HJ. Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX). Proc. Am. Soc. Clin. Oncol.22(14S), (2004) (Abstract 3600).
   Google Scholar
• Marshall J, Zakari A, Hwang JJ, Papadopoulos V, Rosenberg A, Silver C. Ginkgo Biloba (GB) extract as a neuroprotective agent in oxaliplatin (Ox)-induced neuropathy. Proc. Am. Soc. Clin. Oncol.22(14S), (2004) (Abstract 3670).
   Google Scholar
• Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann. Oncol.12(3), 421–422 (2001).
   PubMed Web of Science ®Google Scholar
• Gedlicka C, Scheithauer W, Schull B, Kornek GV. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with α-lipoic acid. J. Clin. Oncol.20(15), 3359–3361 (2002).
   PubMed Web of Science ®Google Scholar